Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 11/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542426 | 1.00 | KDM1A (0.54) | KDM1ASIGMAR1SRD5A1KDM4CHTR2A | |
| SCHEMBL29436469 | 1.00 | KDM1A (0.54) | KDM1ASIGMAR1SRD5A1KDM4CHTR2A | |
| SCHEMBL17550266 | 1.00 | KDM1A (0.54) | KDM1ASIGMAR1SRD5A1KDM4CHTR2A | |
| SCHEMBL12878860 | 0.79 | KDM1A (0.57) | KDM1ASIGMAR1SRD5A1HTR2AHTR2C | |
| SCHEMBL31393901 | 0.77 | AVPR1A (0.42) | KDM1ASIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24538629 | 0.76 | KDM1A (0.54) | KDM1ASIGMAR1SRD5A1HTR2AHTR2C | |
| SCHEMBL29190476 | 0.76 | SLC6A4 (0.41) | KDM1A | |
| SCHEMBL28883100 | 0.75 | KDM1A (0.57) | KDM1ASIGMAR1SRD5A1KDM4CHTR2A | |
| SCHEMBL21930256 | 0.74 | SRD5A1 (0.36) | KDM1ASRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL11197926 | 0.74 | KDM1A (0.51) | KDM1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM1A 1335/4885SIGMAR1 4291/4885SRD5A1 4061/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885SRD5A1 4195/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885SRD5A1 4195/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | KDM1A 1212/4885SIGMAR1 4041/4885SRD5A1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.